MCID: BRN004
MIFTS: 56

Brain Edema

Categories: Eye diseases, Neuronal diseases

Aliases & Classifications for Brain Edema

MalaCards integrated aliases for Brain Edema:

Name: Brain Edema 12 54 43 15 17 71
Intracranial Swelling 12
Cerebral Edema 71
Wet Brain 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4724
MeSH 43 D001929
UMLS 71 C0006114 C1527311

Summaries for Brain Edema

Disease Ontology : 12 A brain disease that is characterized by excess accumulation of fluid in the intracellular and/or extracellular spaces of the brain, has symptom nausea, has symptom vomiting, has symptom blurred vision, has symptom seizure, has symptom coma.

MalaCards based summary : Brain Edema, also known as intracranial swelling, is related to intracranial hypertension and traumatic brain injury, and has symptoms including vomiting, coma and blurred vision. An important gene associated with Brain Edema is AQP4 (Aquaporin 4), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and Pathways in cancer. The drugs Nicardipine and Tramadol have been mentioned in the context of this disorder. Affiliated tissues include brain, liver and endothelial, and related phenotypes are cardiovascular system and behavior/neurological

Wikipedia : 74 Cerebral edema is excess accumulation of fluid (edema) in the intracellular or extracellular spaces of... more...

Related Diseases for Brain Edema

Diseases related to Brain Edema via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 471)
# Related Disease Score Top Affiliating Genes
1 intracranial hypertension 31.5 IL1B AQP4 AQP1 ALB
2 traumatic brain injury 31.2 MMP9 IL6 GFAP AQP4
3 hepatic encephalopathy 31.1 SLC25A13 MMP9 IL6 GLUL AQP4 ALB
4 eclampsia 31.0 VEGFA IL6 ALB
5 hydrops, lactic acidosis, and sideroblastic anemia 31.0 VEGFA MIP KNG1 AQP4 ALB
6 meningoencephalitis 30.9 IL6 IL1B CLDN5 ALB
7 meningitis 30.8 VEGFA MMP9 IL6 IL1B AQP4 ALB
8 stroke, ischemic 30.8 VEGFA MMP9 IL6 IL1B AQP4 ALB
9 arteriovenous malformation 30.7 VEGFA MMP9 IL6 IL1B
10 ischemia 30.6 VEGFA SOD1 KNG1 HMOX1 GFAP
11 bacterial meningitis 30.6 TJP1 MMP9 IL6 IL1B AQP4 ALB
12 end stage renal disease 30.6 VEGFA IL6 BDKRB2 ALB
13 arteriovenous malformations of the brain 30.5 VEGFA MMP9 IL6
14 obstructive hydrocephalus 30.4 GFAP AQP4 AQP1
15 proteasome-associated autoinflammatory syndrome 1 30.4 MMP9 IL6 IL1B
16 pulmonary edema 30.4 KNG1 IL1B HMOX1
17 dysentery 30.3 IL6 IL1B ALB
18 reye syndrome 30.3 OTC GLUL ALB
19 common cold 30.3 IL6 IL1B ALB
20 exanthem 30.2 VEGFA IL6 IL1B ALB
21 encephalitis 30.1 TJP1 IL6 IL1B GFAP AQP4
22 demyelinating disease 30.1 MMP9 IL6 IL1B AQP4
23 glioblastoma multiforme 29.9 VEGFA MMP9 IL6 IL1B GFAP CLDN5
24 spinal cord injury 29.9 MMP9 IL6 GFAP AQP4
25 migraine with or without aura 1 29.9 MMP9 KNG1 IL6 IL1B AQP4 ALB
26 encephalomalacia 29.8 IL6 IL1B GFAP
27 malaria 29.8 VEGFA TJP1 SOD1 MMP9 IL6 IL1B
28 normal pressure hydrocephalus 29.7 VEGFA GFAP AQP4
29 neuroma 29.7 IL6 GFAP AQP4 AQP1
30 chiari malformation 29.7 GFAP AQP1
31 vascular disease 29.7 VEGFA SOD1 MMP9 KNG1 IL6 HMOX1
32 pneumothorax 29.6 MMP9 HMOX1 GFAP
33 pre-eclampsia 29.3 VEGFA SOD1 MMP9 KNG1 IL6 IL1B
34 peripheral nervous system disease 29.1 VEGFA SOD1 KNG1 IL6 IL1B GFAP
35 encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy, 1 12.7
36 encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy, 2 12.6
37 citrullinemia, type ii, adult-onset 11.2
38 encephalopathy, acute, infection-induced 4 11.2
39 mitochondrial complex i deficiency, nuclear type 20 11.0
40 meningitis and encephalitis 10.7 SOD1 ALB
41 cerebral artery occlusion 10.7
42 brain injury 10.6
43 dysferlinopathy 10.6 MIP AQP4 AQP1
44 hantavirus hemorrhagic fever with renal syndrome 10.6 VEGFA IL6 ALB
45 inappropriate adh syndrome 10.6 AQP4 AQP1 ALB
46 intestinal perforation 10.6 VEGFA IL6 ALB
47 myelitis 10.6 MMP9 IL6 AQP4
48 communicating hydrocephalus 10.6 AQP4 AQP1 ALB
49 intussusception 10.6 VEGFA IL6 ALB
50 acute transverse myelitis 10.6 MMP9 IL6 AQP4

Comorbidity relations with Brain Edema via Phenotypic Disease Network (PDN):


Acute Cystitis Brain Cancer
Brain Compression Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Hypertension, Essential

Graphical network of the top 20 diseases related to Brain Edema:



Diseases related to Brain Edema

Symptoms & Phenotypes for Brain Edema

Symptoms:

12
  • vomiting
  • coma
  • blurred vision
  • nausea
  • seizure

UMLS symptoms related to Brain Edema:


edema, headache, peau d'orange

MGI Mouse Phenotypes related to Brain Edema:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.35 ALB AQP1 AQP4 BDKRB2 CLDN5 GFAP
2 behavior/neurological MP:0005386 10.34 AQP1 AQP4 BDKRB2 GFAP GLUL HMOX1
3 homeostasis/metabolism MP:0005376 10.3 ALB AQP1 AQP4 BDKRB2 GFAP GLUL
4 growth/size/body region MP:0005378 10.25 AQP1 AQP4 GFAP GLUL HMOX1 IL1B
5 cellular MP:0005384 10.2 ALB BDKRB2 GFAP GLUL HMOX1 IL6
6 endocrine/exocrine gland MP:0005379 10.09 ALB AQP1 AQP4 BDKRB2 HMOX1 IL6
7 immune system MP:0005387 10.06 ALB AQP4 BDKRB2 GFAP HMOX1 IL1B
8 mortality/aging MP:0010768 10.06 ALB AQP1 AQP4 BDKRB2 CLDN5 GFAP
9 liver/biliary system MP:0005370 9.86 ALB GLUL HMOX1 IL6 OTC SLC25A13
10 nervous system MP:0003631 9.77 AQP1 AQP4 CLDN5 GFAP GLUL IL1B
11 renal/urinary system MP:0005367 9.36 ALB AQP1 AQP4 BDKRB2 HMOX1 IL6

Drugs & Therapeutics for Brain Edema

Drugs for Brain Edema (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 254)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicardipine Approved, Investigational Phase 4 55985-32-5 4474
2
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
3
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
4
Norepinephrine Approved Phase 4 51-41-2 439260
5
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
6
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
7
Argatroban Approved, Investigational Phase 4 74863-84-6 152951
8
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
9
Conivaptan Approved, Investigational Phase 4 210101-16-9 151171
10 diuretics Phase 4
11 Carbonic Anhydrase Inhibitors Phase 4
12 Liver Extracts Phase 4
13 Adrenergic alpha-Agonists Phase 4
14 Adrenergic Agonists Phase 4
15 Analgesics, Non-Narcotic Phase 4
16 Platelet Aggregation Inhibitors Phase 4
17 Hypnotics and Sedatives Phase 4
18
protease inhibitors Phase 4
19 HIV Protease Inhibitors Phase 4
20 Anti-Bacterial Agents Phase 4
21 Antibiotics, Antitubercular Phase 4
22 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
23 Antithrombins Phase 4
24 Antithrombin III Phase 4
25 Serine Proteinase Inhibitors Phase 4
26 Anticoagulants Phase 4
27 Hormone Antagonists Phase 4
28 Progestins Phase 4
29 Pharmaceutical Solutions Phase 4
30 Vasopressins Phase 4
31 Arginine Vasopressin Phase 4
32
Serine Investigational, Nutraceutical Phase 4 56-45-1 5951
33
Propofol Approved, Investigational, Vet_approved Phase 2, Phase 3 2078-54-8 4943
34
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
35
Misoprostol Approved Phase 3 59122-46-2 5282381
36
Carbetocin Approved, Investigational Phase 3 37025-55-1 71715 16681432
37
Glyburide Approved Phase 3 10238-21-8 3488
38
Artesunate Approved, Investigational Phase 3 88495-63-0 6917864 5464098
39
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 2, Phase 3 437-38-7 3345
40
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
41
Vitamin C Approved, Nutraceutical Phase 3 50-81-7 5785 54670067
42 Tocotrienol Investigational Phase 3 6829-55-6
43 3-n-butylphthalide Phase 3
44 Alpha-lipoic Acid Phase 3
45 Antioxidants Phase 3
46 Thioctic Acid Phase 3
47 Tocotrienols Phase 3
48 Tocopherols Phase 3
49 Antacids Phase 3
50 Anti-Ulcer Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 218)
# Name Status NCT ID Phase Drugs
1 An Open-Label Prospective Study to Evaluate the Safety and Efficacy of Double or Triple Concentrated Intravenous Nicardipine for Treatment of Hypertension in Patients With Ischemic Stroke, Intracerebral Hemorrhage or Subarachnoid Hemorrhage Unknown status NCT00325793 Phase 4 Nicardipine
2 Effect of Single Dose of Tramadol on Extubation Response and Quality of Emergence(Cough and Nausea Vomiting) Following Supratentorial Intracranial Surgery Unknown status NCT02964416 Phase 4 Injection Tramadol
3 Effect of Isosmotic Doses of Mannitol 20% Versus Hypertonic Saline 7.5% in Brain Metabolism and Oxygenation in Supratentorial Craniotomies Completed NCT03573999 Phase 4 Mannitol;NaCl 7.5%
4 Correlation of Measured and Calculated Serum Osmolality During Mannitol or Hypertonic Saline Infusion in Patients After Craniotomy Completed NCT02037815 Phase 4 20% mannitol solution, 125 ml, IV infusion in 15 min;3.1% sodium chloride solution, 125 ml, IV infusion in 15 min
5 Micronized Oral Progesterone and Effect on Time Symptomatic From Concussion: A Pilot Study Completed NCT01809639 Phase 4 Progesterone;Placebo
6 Acetazolamide for the Prevention of High Altitude Illness: a Comparison of Dosing Completed NCT01993667 Phase 4 Low Dose Acetazolamide;Normal Dose Acetazolamide
7 Effects of the Administration of Albumin in Patients With Cirrhosis and Acute Hepatic Encephalopathy. Completed NCT00886925 Phase 4 Albumin;Sodium chloride 0.9%
8 Randomized Controlled Trial of Intravenous Fluid In Severely Injured Paediatric Trauma Patients: Comparison of Normal Saline Versus Ringer's Lactate Completed NCT01692769 Phase 4 Normal Saline;Ringer's Lactate
9 Study on the Relationship Between Asymmetric Vascular Sign of Cortex and Cerebral Edema and Prognosis of Massive Cerebral Infarction Recruiting NCT04247659 Phase 4 sodium aescinate
10 Use of HA 330-II for Hemofiltration in Patients With Acute Liver Failure as a Bridge to Liver Transplantation: Clinical Evaluation Protocol. Recruiting NCT04243655 Phase 4 Standard medical treatment (SMT)
11 Effect of Dexmedetomidine on Brain Homeostasis and Neurocognitive Outcome of Patients Undergoing Brain Tumor Exclusion Recruiting NCT04266665 Phase 4 Dexmedetomidine
12 Clinical Study of Argatroban in the Treatment of Acute Progressive Ischemic Stroke Recruiting NCT04275180 Phase 4 Argatroban
13 An International Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Progesterone Combined Intranasal and Intramuscular Administration in Patients With Acute Hemorrhagic Stroke Not yet recruiting NCT04143880 Phase 4 Progesterone
14 A Single-center Randomized Double Blinded Control Trial of Intravenous Fluid Content in Children With Diabetic Ketoacidosis Admitted to the Pediatric Intensive Care Unit Suspended NCT03066440 Phase 4 Normal saline;Lactated Ringers
15 Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients Terminated NCT00727090 Phase 4 Conivaptan
16 Effect of Clevidipine on Intracranial Pressure, Cerebral Blood Flow, Brain Tissue Oxygenation and Brain Cellular Metabolism in Severely Hypertensive Patients With Acute Brain Injury Withdrawn NCT01526876 Phase 4 clevidipine butyrate
17 High Dose Hyperoncotic Serum Albumin for the Treatment of the Acute Phase of Severe Head Injury Unknown status NCT00152685 Phase 2, Phase 3 human serum albumin
18 Cerebral Vascular Effects of Dexmedetomidine Versus Propofol Sedation in Intubated Mechanically Ventilated ICU Patients With and Without Traumatic Brain Injury. Unknown status NCT03285165 Phase 2, Phase 3 0.2-0.7 mcg/kg/h dexmedetomedine infusion.;10-70 mcg/kg/h propofol infusion.
19 Fluid Therapy and Cerebral Injury in Pediatric Diabetic Ketoacidosis Completed NCT01365793 Phase 3 0.45% saline replacement fluid;0.9% saline replacement fluid;0.45% saline intravenous fluid;0.9% saline Intravenous fluid
20 A Phase III Randomized, Double-Blind, Dexamethasone-Sparing Study Comparing Human Corticotropin-Releasing Factor (hCRF) to Placebo for Control of Symptoms Associated With Peritumoral Brain Edema in Patients With Malignant Brain Tumor Who Require Chronic Administration of High-Dose Dexamethasone Completed NCT00088166 Phase 3 hCRF;placebo hCRF
21 An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302, NTI 0303, or Other Designated Studies Completed NCT00226655 Phase 3 hCRF [XERECEPT (corticorelin acetate injection)]
22 Fluid Shift in Patients Treated With Therapeutic Hypothermia After Cardiac Arrest, and How do They Manage Life Afterwards? Completed NCT00347477 Phase 3 HyperHAES vs. RA-solution/NaCl
23 Butylphthalide for Preventing Restenosis After Intracranial and Extracranial Artery Stenting Completed NCT01405248 Phase 3 Butylphthalide;Placebo
24 Effects of Tolvaptan on Cognitive Function, Brain Metabolism and Quality of Life in Hyponatremic Cirrhotics With Hepatic Encephalopathy: A Prospective Clinical Trial Completed NCT01556646 Phase 3 Tolvaptan
25 Randomized Double-Blind Placebo-Controlled Trial of Oral Anti-Oxidant Supplementation for the Prevention of Acute Mountain Sickness. Completed NCT00664001 Phase 3
26 Carbetocin in Preventing Postpartum Bleeding in Women With Severe Preeclampsia. Completed NCT02086994 Phase 3 misoprostol;carbetocin
27 Risk Reduction of Symptomatic and Silent Brain Infarctions During Cardiac Surgery Due to Ultrasound Activation of Endogenous Fibrinolytic System Using Transcranial Doppler Monitoring Completed NCT01591018 Phase 3
28 Risk Reduction of Symptomatic and Silent Brain Infarctions During Carotid Endarterectomy and Carotid Stenting Due to Ultrasound Activation of Endogenous Fibrinolytic System Using Transcranial Doppler Monitoring Completed NCT01591005 Phase 3
29 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction Recruiting NCT02864953 Phase 3 BIIB093;Placebo
30 Salovum (Antisecretory Factor) in Patients With Severe Traumatic Brain Injury Recruiting NCT03339505 Phase 3
31 Safety and Efficacy of Glibenclamide Combined With Rt-PA in Treating Acute Ischemic Stroke: a Prospective, Randomized, Double-blind, Placebo-control, Multi-center Study Recruiting NCT03284463 Phase 2, Phase 3 Glibenclamide;Placebo
32 Treating Brain Swelling in Pediatric Cerebral Malaria Recruiting NCT03300648 Phase 3 Hypertonic saline
33 Magnesium Sulphate Versus Fentanyl: Effects on the Quality of Bier Block: Double Blind Placebo Controlled Trial Recruiting NCT04393610 Phase 2, Phase 3 Lidocaine;Magnesium Sulphate;Fentanyl
34 Efficacy and Safety of Neuroprotectant Cattle Encephalon Glycoside and Ignotin Injection for Intracerebral Hemorrhage: a Multicenter, Randomized, Double-blinded, Placebo-controlled Trial. Not yet recruiting NCT03546283 Phase 3 Placebos;Cattle Encephalon Glycoside and Ignotin
35 Dexamethasone for the Treatment of Traumatic Brain Injured Patients With Brain Contusions and Pericontusional Edema: Study Protocol for a Prospective, Randomized and Double Blind Trial. Not yet recruiting NCT04303065 Phase 3 Dexamethasone Oral;Placebo oral tablet
36 Decompressive Craniectomy In Malignant Middle Cerebral Artery Infarcts : A Sequential Design, Multicenter, Randomized, Controlled Trial Terminated NCT00190203 Phase 3
37 Does Cleansing of Suction Blood During Cardiac Surgery With Heart and Lung Machine Reduce the Postoperative Inflammatory Response ? Terminated NCT00159926 Phase 3
38 A Phase III Randomized, Double-Blind Study Comparing Human Corticotropin-Releasing Factor (hCRF) to Dexamethasone for Control of Symptoms Associated With Peritumoral Brain Edema in Patients With Primary Malignant Glioma Withdrawn NCT00226668 Phase 3 hCRF;placebo hCRF
39 Labetalol Versus MgSO4 for the Prevention of Eclampsia Trial (LAMPET) Withdrawn NCT00293735 Phase 2, Phase 3 labetalol (seizure prevention);MgSO4 (seizure prevention)
40 Evaluation and Correlation Between the Disruption in Blood-brain-barrier and the Development of Secondary Brain Edema Associated With Brain Damage by Using MRI in Patients With Various Types of Intra-cranial Bleeding Unknown status NCT01830894 Phase 1, Phase 2
41 Safety and Tolerability of a Protocol of Targeted Temperature Management After Intracerebral Hemorrhage Unknown status NCT01866384 Phase 2
42 Prospective, Double-blind, Randomized, Placebo-controlled Trial of Ibuprofen Versus Placebo for Prevention of Neurologic Forms of Altitude Sickness Unknown status NCT01606527 Phase 2 Ibuprofen 600mg orally three times daily
43 Ibuprofen Versus Acetaminophen for Treatment of Mild Traumatic Brain Injury Unknown status NCT02443142 Phase 2 Ibuprofen;Acetaminophen
44 High-Dose Methotrexate Plus Steroid Followed by Concurrent Whole Brain Chemoradiation With Temozolomide for Immunocompetent Patients With Primary Central Nervous System Lymphoma – a Phase II Study Unknown status NCT00455286 Phase 2 Methotrexate;Methylprednisolone;Temozolomide
45 Intraosseous Administration of Hypertonic Saline in Acute Brain-injured Patients: A Prospective Case Series and Literature Review Completed NCT03276494 Phase 2 Hypertonic saline
46 Comparison of Balanced Crystalloid Solution and 0,9% Sodium Chloride in Children Undergoing Brain Tumor Resection: a Randomized Controlled Trial Completed NCT02707549 Phase 2 balanced crystalloid solution (components: sodium chloride, sodium gluconate, sodium acetate, potassium chloride and magnesium chloride);0.9% sodium chloride
47 Astragalus Membranaceus for Brain Edema Induced by Hemorrhagic Stroke Completed NCT01428401 Phase 2 Chinese Herb Astragalus membranaceus
48 Double-blind, Randomized, Placebo Controlled, Dose-finding Phase 2 Clinical Trial of Intravenous Deferoxamine in Patients With Acute Ischemic Stroke Treated With Tissue Plasminogen Activator Completed NCT00777140 Phase 2 Deferoxamine
49 A Modified Phase I/II Trial Of Rapamycin In Patients With Glioblastoma Multiforme Completed NCT00047073 Phase 1, Phase 2 Rapamycin
50 Glutaminergic and Histaminergic Pathway Modulation in Acute Ischemic Stroke as an Effective Neuroprotection Strategy. Completed NCT02142712 Phase 2 Diphenhydramine;Pantoprazole;Famotidine;Dextromethorphan

Search NIH Clinical Center for Brain Edema

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Dexamethasone
dexamethasone acetate
DEXAMETHASONE ACETATE PWDR
Dexamethasone phosphate
Dexamethasone sodium phosphate
DEXAMETHASONE SODIUM PHOSPHATE PWDR
Mannitol
Mannitol hexanitrate
MANNITOL PWDR

Cochrane evidence based reviews: brain edema

Genetic Tests for Brain Edema

Anatomical Context for Brain Edema

MalaCards organs/tissues related to Brain Edema:

40
Brain, Liver, Endothelial, Cortex, Lung, Bone, Neutrophil

Publications for Brain Edema

Articles related to Brain Edema:

(show top 50) (show all 6726)
# Title Authors PMID Year
1
Mechanisms of cerebral edema in traumatic brain injury: therapeutic developments. 61 54
20168229 2010
2
Aquaporin-4 and traumatic brain edema. 61 54
20356447 2010
3
Ammonia and proinflammatory cytokines modify expression of genes coding for astrocytic proteins implicated in brain edema in acute liver failure. 54 61
20217200 2010
4
[Regulation, structure and function of brain aquaporin]. 54 61
20030210 2009
5
[AQP4 expression in the brains of patients with glioblastoma and its association with brain edema]. 61 54
19764565 2009
6
Roles of aquaporin-4 isoforms and amino acids in square array assembly. 54 61
19445480 2009
7
Role of bradykinin and catecholamines in cerebral infarction and brain edema. 61 54
19265042 2009
8
Acetazolamide reversibly inhibits water conduction by aquaporin-4. 61 54
19114109 2009
9
Hypoxia-inducible factor-1alpha signaling in aquaporin upregulation after traumatic brain injury. 61 54
19429018 2009
10
Actin cytoskeleton remodeling governs aquaporin-4 localization in astrocytes. 61 54
18649401 2008
11
[The relationship between the aquaporin-4 and brain edema, pathologic change, ultrastructure in peri-hematoma tissue in patients with intracerebral hemorrhage]. 54 61
19000426 2008
12
Lack of aquaporin-4 water transport inhibition by antiepileptics and arylsulfonamides. 61 54
18572411 2008
13
The expression and the role of protease nexin-1 on brain edema after intracerebral hemorrhage. 61 54
18442833 2008
14
High serum levels of endothelin-1 predict severe cerebral edema in patients with acute ischemic stroke treated with t-PA. 61 54
18436890 2008
15
The role of aquaporin-4 polymorphisms in the development of brain edema after middle cerebral artery occlusion. 54 61
18309154 2008
16
Aquaporin-4 in hepatic encephalopathy. 54 61
17879149 2007
17
Can variation in aquaporin 4 gene be associated with different outcomes in traumatic brain edema? 61 54
17890008 2007
18
Aquaporins: multiple roles in the central nervous system. 54 61
17901256 2007
19
Temporal and regional evolution of aquaporin-4 expression and magnetic resonance imaging in a rat pup model of neonatal stroke. 54 61
17622964 2007
20
Expression pattern of the water channel aquaporin-4 in human gliomas is associated with blood-brain barrier disturbance but not with patient survival. 61 54
17335082 2007
21
Aquaporin 4 regulation during acute and long-term experimental Herpes simplex virus encephalitis. 54 61
17454447 2007
22
Aquaporins as targets for drug discovery. 61 54
17692010 2007
23
Control of brain glutamine synthesis by NMDA receptors. 54 61
17127345 2007
24
[Personal recollection of episodes devoted to my study of neuropathology]. 54 61
17432177 2006
25
Astrocyte end-feet in germinal matrix, cerebral cortex, and white matter in developing infants. 61 54
16627880 2006
26
Astrocytes co-express aquaporin-1, -4, and vascular endothelial growth factor in brain edema tissue associated with brain contusion. 61 54
16671493 2006
27
Sulforaphane enhances aquaporin-4 expression and decreases cerebral edema following traumatic brain injury. 61 54
16211562 2005
28
[Brain edema and aquaporin]. 54 61
16313100 2005
29
Enhanced expression of aquaporin 4 in human brain with inflammatory diseases. 54 61
16133546 2005
30
Endothelin-1 overexpression leads to further water accumulation and brain edema after middle cerebral artery occlusion via aquaporin 4 expression in astrocytic end-feet. 54 61
15815585 2005
31
[Protective effects of total paeony glycoside against global cerebral ischemia-reperfusion injury in gerbils]. 54 61
15837661 2005
32
Blood-brain barrier disruption highly induces aquaporin-4 mRNA and protein in perivascular and parenchymal astrocytes: protective effect by estradiol treatment in ovariectomized animals. 54 61
15772982 2005
33
Risk of worsened encephalopathy after intravenous glycerol therapy in patients with adult-onset type II citrullinemia (CTLN2). 54 61
15805705 2005
34
In vivo expression of aquaporin-4 by reactive microglia. 61 54
15525343 2004
35
Molecular mechanisms and drug development in aquaporin water channel diseases: structure and function of aquaporins. 61 54
15557734 2004
36
Aquaporin water channels in central nervous system. 61 54
16181079 2004
37
Aquaporins and brain edema. 61 54
15120208 2004
38
Alpha-syntrophin deletion removes the perivascular but not endothelial pool of aquaporin-4 at the blood-brain barrier and delays the development of brain edema in an experimental model of acute hyponatremia. 61 54
14734638 2004
39
Importance of aquaporins in the physiopathology of brain edema. 61 54
15281891 2004
40
Regulation of brain aquaporins. 61 54
15561410 2004
41
Aquaporin water channels: molecular mechanisms for human diseases. 54 61
14630322 2003
42
Enhanced expression of aquaporin 4 in human brain with infarction. 54 61
12715185 2003
43
Inhibition of aquaporin-4 expression in astrocytes by RNAi determines alteration in cell morphology, growth, and water transport and induces changes in ischemia-related genes. 61 54
12824287 2003
44
[Relationship between aquaporin-4 expression in astrocytes and brain edema caused by glioma]. 61 54
12810377 2003
45
Testosterone up-regulates aquaporin-4 expression in cultured astrocytes. 54 61
12774311 2003
46
Pathophysiology of traumatic brain edema: current concepts. 61 54
14753394 2003
47
Therapeutical efficacy of a novel non-peptide bradykinin B2 receptor antagonist on brain edema formation and ischemic tissue damage in focal cerebral ischemia. 61 54
14753436 2003
48
Bench to bedside: brain edema and cerebral resuscitation: the present and future. 61 54
12208684 2002
49
Aquaporins in the central nervous system. 54 61
11115728 2001
50
LF16-0687 a novel non-peptide bradykinin B2 receptor antagonist reduces vasogenic brain edema from a focal lesion in rats. 61 54
11449993 2000

Variations for Brain Edema

Expression for Brain Edema

Search GEO for disease gene expression data for Brain Edema.

Pathways for Brain Edema

Pathways related to Brain Edema according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.9 MMP9 KNG1 IL6 IL1B CLDN5 BDKRB2
2 12.52 VEGFA MMP9 KNG1 IL6 HMOX1 BDKRB2
3
Show member pathways
12.18 SOD1 IL6 IL1B ALB
4 12.11 TJP1 IL6 IL1B CLDN5
5 12.01 VEGFA IL6 IL1B AQP4
6 11.92 VEGFA MMP9 IL1B HMOX1
7 11.41 VEGFA MMP9 IL6 IL1B HMOX1
8 11.37 MMP9 KNG1 IL6
9
Show member pathways
11.36 VEGFA MMP9 IL6 IL1B
10 11.26 MMP9 IL6 IL1B HMOX1
11 11.2 KNG1 IL6 IL1B
12 11.18 MMP9 IL6 IL1B GFAP AQP4 AQP1
13 11.15 SOD1 IL6 IL1B
14 11.12 IL6 IL1B HMOX1
15 11.08 MMP9 IL6 HMOX1
16 10.64 IL6 IL1B

GO Terms for Brain Edema

Cellular components related to Brain Edema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.97 VEGFA SOD1 NAXE MMP9 KNG1 IL6
2 extracellular space GO:0005615 9.61 VEGFA SOD1 NAXE MMP9 KNG1 IL6
3 platelet alpha granule lumen GO:0031093 9.43 VEGFA KNG1 ALB
4 cell GO:0005623 9.23 TJP1 SOD1 KNG1 IL6 HMOX1 BDKRB2
5 astrocyte end-foot GO:0097450 9.16 GFAP AQP4

Biological processes related to Brain Edema according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.89 SOD1 MMP9 KNG1 IL6 HMOX1
2 negative regulation of apoptotic process GO:0043066 9.88 VEGFA SOD1 MMP9 IL6 AQP1 ALB
3 positive regulation of cell migration GO:0030335 9.85 VEGFA TJP1 MMP9 IL1B
4 positive regulation of angiogenesis GO:0045766 9.78 VEGFA IL1B HMOX1 AQP1
5 cytokine-mediated signaling pathway GO:0019221 9.77 VEGFA MMP9 IL6 IL1B HMOX1
6 embryo implantation GO:0007566 9.63 SOD1 MMP9 IL1B
7 platelet degranulation GO:0002576 9.62 VEGFA SOD1 KNG1 ALB
8 cellular response to cadmium ion GO:0071276 9.61 SOD1 MMP9 HMOX1
9 positive regulation of neuroinflammatory response GO:0150078 9.56 IL6 IL1B
10 regulation of neuroinflammatory response GO:0150077 9.54 MMP9 IL6
11 multicellular organismal water homeostasis GO:0050891 9.52 AQP4 AQP1
12 cellular water homeostasis GO:0009992 9.51 AQP4 AQP1
13 maintenance of permeability of blood-brain barrier GO:0035633 9.43 TJP1 IL6 CLDN5
14 nicotinamide nucleotide metabolic process GO:0046496 9.16 NAXE NAXD
15 positive regulation of glial cell proliferation GO:0060252 9.13 IL6 IL1B GFAP
16 water transport GO:0006833 8.8 MIP AQP4 AQP1

Molecular functions related to Brain Edema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.4 VEGFA SOD1 SLC25A13 OTC NAXE MMP9
2 channel activity GO:0015267 9.33 MIP AQP4 AQP1
3 water channel activity GO:0015250 9.13 MIP AQP4 AQP1

Sources for Brain Edema

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....